Is Zepbound a semaglutide? No—Zepbound is tirzepatide, not semaglutide. Learn the key differences, uses, and safety facts in this complete guide.
No, Zepbound is not a semaglutide. Zepbound contains tirzepatide, a dual GIP and GLP-1 receptor agonist, while semaglutide is a GLP-1 receptor agonist. They are different active ingredients, though both belong to the same family of incretin-based medications.
What Is Zepbound?
Zepbound is the brand name for tirzepatide when it is prescribed for chronic weight management. The FDA approved Zepbound in November 2023 for adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) who also have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
Tirzepatide is also sold under the brand name Mounjaro for type 2 diabetes. Zepbound works by activating two hormone receptors—GIP and GLP-1—which can reduce appetite and food intake. It is given as a once-weekly injection under the skin, with doses gradually increased over several weeks to minimize side effects.
The starting dose is 2.5 mg, and it is gradually increased over 4 to 20 weeks to a maintenance dose of 5 mg, 10 mg, or 15 mg, depending on tolerance and results.
What Is Semaglutide?
If you are asking what is semaglutide, it is a GLP-1 receptor agonist that mimics a gut hormone to help regulate appetite, blood sugar, and digestion. Semaglutide is the active ingredient in Ozempic (for type 2 diabetes), Wegovy (for weight loss), and Rybelsus (an oral tablet for diabetes).
A common question is is ozempic semaglutide, and the answer is yes—Ozempic is one brand of semaglutide. Semaglutide is also available in compounded forms, which are not FDA-approved. Semaglutide has been studied for years and has a well-established safety profile when used as directed.
Semaglutide is available as a once-weekly injection (Ozempic, Wegovy) or a daily oral tablet (Rybelsus). Wegovy is approved for weight loss at higher doses than Ozempic, which is used for diabetes. Rybelsus is only approved for type 2 diabetes, not weight loss.
Zepbound vs. Semaglutide: Key Differences
Here is a side-by-side comparison of the two medications.
| Feature | Zepbound (tirzepatide) | Semaglutide (Wegovy/Ozempic) |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Mechanism | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Brand names | Zepbound (weight loss), Mounjaro (diabetes) | Wegovy (weight loss), Ozempic (diabetes), Rybelsus (diabetes) |
| FDA-approved for weight loss | Yes | Yes (Wegovy) |
| FDA-approved for type 2 diabetes | Yes (Mounjaro) | Yes (Ozempic, Rybelsus) |
| Administration | Weekly injection | Weekly injection or daily oral (Rybelsus) |
| Common side effects | Nausea, diarrhea, vomiting, constipation | Nausea, diarrhea, vomiting, constipation |
The most notable difference is that Zepbound targets two hormone receptors, while semaglutide targets only GLP-1. This dual action is thought to contribute to tirzepatide's slightly greater average weight loss in clinical trials.
Are They Used for the Same Conditions?
Both medications are used for chronic weight management and type 2 diabetes, but the specific brands are approved for different conditions. Zepbound is only approved for weight loss, while Mounjaro is approved for type 2 diabetes. Semaglutide has separate brands for each condition: Wegovy for weight loss and Ozempic or Rybelsus for diabetes.
Doctors may prescribe either medication off-label for other uses, such as prediabetes or metabolic syndrome, but this is not FDA-approved. You should discuss any off-label use with a healthcare professional who can evaluate the risks and benefits.
Both drugs are also being studied for other conditions, including heart disease, fatty liver disease, and sleep apnea. However, only the FDA-approved indications should guide prescribing. Insurance coverage varies widely for both medications.
Safety and Side Effects
Both Zepbound and semaglutide carry a boxed warning for thyroid C-cell tumors. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. Tell your doctor if you have a history of pancreatitis, gallbladder disease, or kidney problems.
Common side effects include nausea, vomiting, diarrhea, and constipation. These typically improve as your body adjusts. Serious risks include pancreatitis, gallbladder disease, and kidney injury. Many people ask is semaglutide safe, and while it is FDA-approved for specific uses, it is not safe for everyone. Always consult a healthcare professional before starting treatment.
You should not use Zepbound or semaglutide if you are pregnant or planning to become pregnant. These medications may harm a developing fetus. Also, tell your doctor about all other medications you take, as interactions can occur.
Compounded Versions and Online Purchases
Compounded semaglutide and tirzepatide are custom-made by compounding pharmacies and are not FDA-approved. If you wonder what is compounded semaglutide, it is a version of the drug made from bulk ingredients, often during shortages. Compounded drugs may contain different forms of the active ingredient and may not have the same purity or potency as FDA-approved brands.
You might also ask is it safe to buy semaglutide online, and the FDA warns that online sellers may be unlicensed or sell counterfeit products. Only use FDA-approved medications from licensed pharmacies with a prescription. Your healthcare provider can help you find a legitimate source.
The FDA has warned that some compounded semaglutide products have been found to contain impurities or incorrect dosages. Compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality. If you choose a compounded product, work with a reputable pharmacy and your doctor.
Which Is Better: Semaglutide, Tirzepatide, or Retatrutide?
A frequent debate is which medication is better: semaglutide, tirzepatide, or retatrutide. Clinical trials suggest tirzepatide (Zepbound) may produce greater average weight loss than semaglutide (Wegovy), but individual responses vary. Some people lose more weight on semaglutide, and tolerability can differ.
Head-to-head trials directly comparing Zepbound and Wegovy are limited. The SURMOUNT trials for tirzepatide and STEP trials for semaglutide showed average weight losses of about 20% and 15%, respectively, but these were separate studies. Your personal results may differ.
Retatrutide is an investigational triple agonist that is not yet FDA-approved. It targets GLP-1, GIP, and glucagon receptors and has shown promising weight loss results in early trials. The best choice depends on your health history, goals, and tolerance, so discuss options with your doctor.
Frequently Asked Questions
Is Zepbound the same as semaglutide?
No. Zepbound is the brand name for tirzepatide, while semaglutide is a different active ingredient. They are both used for weight loss but work on different hormone receptors.
What is the difference between Zepbound and Wegovy?
Zepbound contains tirzepatide, a dual GIP/GLP-1 agonist, while Wegovy contains semaglutide, a GLP-1 agonist. Both are FDA-approved for weight loss, but clinical trials suggest tirzepatide may lead to greater average weight loss. Side effects are similar.
Can I take Zepbound if I'm allergic to semaglutide?
Because they are different molecules, an allergy to semaglutide does not necessarily mean you are allergic to tirzepatide. However, you should consult a healthcare provider before switching medications. They can assess your risk and recommend alternatives.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.